Exact Mass: 720.3145608
Exact Mass Matches: 720.3145608
Found 86 metabolites which its exact mass value is equals to given mass value 720.3145608,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Ritonavir
Ritonavir is only found in individuals that have used or taken this drug. It is an HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. [PubChem]Ritonavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AE - Protease inhibitors D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065692 - Cytochrome P-450 CYP3A Inhibitors COVID info from Guide to PHARMACOLOGY, DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
PC(2:0/LTE4)
PC(2:0/LTE4) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/LTE4), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Leukotriene E4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
PC(LTE4/2:0)
PC(LTE4/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(LTE4/2:0), in particular, consists of one chain of one Leukotriene E4 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
16alpha-[(6-O-sulfo-beta-D-glucopyranosyl)oxy]pregn-5-en-20-ol-3beta-yl O-beta-D-oleandropyranoside
Ritonavir
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AE - Protease inhibitors D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065692 - Cytochrome P-450 CYP3A Inhibitors COVID info from Guide to PHARMACOLOGY, DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; INTERNAL_ID 2192 CONFIDENCE standard compound; EAWAG_UCHEM_ID 2580 EAWAG_UCHEM_ID 2580; CONFIDENCE standard compound
As-PL(16:0/0:0)
(S)-Fmoc-2-amino-5-[(N-Pbf-N-tert-butoxy)-guanidino]-pentanoic acid
N,N-diphenyl-N,N-bis(9,9-dimethylfluoren-2-yl)benzidine
N-[3-hydroxy-5-[[3-methyl-2-[[[methyl-[(2-propan-2-yl-4-thiazolyl)methyl]amino]-oxomethyl]amino]-1-oxobutyl]amino]-1,6-diphenylhexan-2-yl]carbamic acid 5-thiazolylmethyl ester
1,3-thiazol-5-ylmethyl N-[(2S,5S)-3-hydroxy-5-[[3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
3-[(2Z,6Z,17Z,24R)-14-ethenyl-22,23-bis(methoxycarbonyl)-5-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8,10,13,15,17,19,21-undecaen-9-yl]propanoic acid
N-[(2R,3R,4R,5S,6R)-5-[(2S,3R,4S,5R,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-4-hydroxy-2-methoxyoxan-3-yl]acetamide
1,3-thiazol-5-ylmethyl N-[(2R,3R,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
1,3-thiazol-5-ylmethyl N-[(2R,5S)-3-hydroxy-5-[[3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
SB-435495
C38H40F4N6O2S (720.2869428000001)
SB-435495 is a potent, selective, reversible, non-covalent and orally active Lp-PLA2 inhibitor with an IC50 of 0.06 nM[1][3].
(1r,4r,5r,7s,8r,9r,10r,11s,12s)-5,7-bis(acetyloxy)-10-[(3r,5s)-5-(acetyloxy)-3-(furan-3-yl)-2-methylcyclopent-1-en-1-yl]-9-(2-methoxy-2-oxoethyl)-4,8,10-trimethyl-2-oxatricyclo[6.3.1.0⁴,¹²]dodecan-11-yl benzoate
(1r,3s,4s,5r,6r,8r,9r,11r,13r,14r,15s,16s)-9,11,16-tris(acetyloxy)-13-(benzoyloxy)-3,8,12,12,15-pentamethyl-7,17-dioxatetracyclo[12.2.1.0¹,⁵.0⁶,⁸]heptadecan-4-yl benzoate
1-(3r)-2-hydroxy-2,6-dimethyl-8-({7-oxofuro[3,2-g]chromen-4-yl}oxy)oct-6-en-3-yl 5-[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-isopropoxyoxan-2-yl]methyl 3-hydroxy-3-methylpentanedioate
(3s,3ar,4r,5r,6r,7as)-6-[(2r,3r,4s)-4-(acetyloxy)-6-hydroxy-2-(2-methoxy-2-oxoethyl)-1,3-dimethyl-7,9-dioxabicyclo[4.2.1]nonan-3-yl]-5-(formyloxy)-3-(furan-3-yl)-7a-hydroxy-3a-methyl-7-methylidene-1-oxo-tetrahydro-2h-inden-4-yl 2-hydroxy-3-methylpentanoate
(1s,2s,6s,7s,9r,11s,13r,14r,16r,17s)-4-methoxy-2,6,14,17-tetramethyl-3-oxo-14-[(3s)-5-oxooxolane-3-carbonyl]-11-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-4-en-16-yl (2e)-2-methylbut-2-enoate
[3,4,5-trihydroxy-6-({7-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-1-(1-hydroxyethyl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl}oxy)oxan-2-yl]methoxysulfonic acid
4-[(2s,3s,4r,5r)-3-{[(2s,3s)-4-hydroxy-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butoxy]methyl}-5-(4-hydroxy-3-methoxyphenyl)-4-(hydroxymethyl)oxolan-2-yl]-2-methoxyphenol
[(2r,3r,4s,5r,6s)-3,4,5-tris(acetyloxy)-6-{[(1r,8s,10r,12s)-8-(acetyloxy)-3,12-dihydroxy-5-isopropyl-11,11-dimethyl-13-oxatetracyclo[10.2.2.0¹,¹⁰.0²,⁷]hexadeca-2,4,6-trien-4-yl]oxy}oxan-2-yl]methyl acetate
[(2r,3s,4s,5r,6r)-6-{[(1s,2r,3as,3bs,7s,9ar,9bs,11as)-7-{[(2r,4r,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-1-[(1s)-1-hydroxyethyl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methoxysulfonic acid
(2s)-2-{[(2r)-6-amino-2-{[(2,3-dihydroxyphenyl)(hydroxy)methylidene]amino}-1-hydroxyhexylidene]amino}-3-{[(2s)-2-{[(2r)-6-amino-2-{[(2,3-dihydroxyphenyl)(hydroxy)methylidene]amino}-1-hydroxyhexylidene]amino}-3-hydroxypropanoyl]oxy}propanoic acid
4-methoxy-2,6,14,17-tetramethyl-3-oxo-14-(5-oxooxolane-3-carbonyl)-11-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-4-en-16-yl 2-methylbut-2-enoate
(2r,3r,4s,5s,6r)-2-{[(4e,12e)-1,7-dihydroxytetradeca-4,12-dien-8,10-diyn-6-yl]oxy}-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol
(1s,2s,4s,7r,9r,11s,13s,14r,15s,16s,17s)-4-(acetyloxy)-15-methoxy-2,14,17-trimethyl-3-oxo-11-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadecan-16-yl 2h-1,3-benzodioxole-5-carboxylate
5,7-bis(acetyloxy)-10-[5-(acetyloxy)-3-(furan-3-yl)-2-methylcyclopent-1-en-1-yl]-9-(2-methoxy-2-oxoethyl)-4,8,10-trimethyl-2-oxatricyclo[6.3.1.0⁴,¹²]dodecan-11-yl benzoate
3',15-dihydroxy-7,14'-dimethyl-3,9,10',11,16',18',22-heptaoxaspiro[heptacyclo[15.6.1.1⁷,¹⁰.0¹,¹⁴.0⁴,¹³.0¹⁸,²³.0¹³,²⁵]pentacosane-21,6'-hexacyclo[12.5.1.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁷,²⁰]henicosan]-18(23)-ene-2,7',9'-trione
6-[4-(acetyloxy)-6-hydroxy-2-(2-methoxy-2-oxoethyl)-1,3-dimethyl-7,9-dioxabicyclo[4.2.1]nonan-3-yl]-5-(formyloxy)-3-(furan-3-yl)-7a-hydroxy-3a-methyl-7-methylidene-1-oxo-tetrahydro-2h-inden-4-yl 2-hydroxy-3-methylpentanoate
(1s,1's,2's,3'r,4s,5's,7r,8's,10s,11's,13s,14s,14'r,15r,17s,17's,20'r,21s,25r)-3',15-dihydroxy-7,14'-dimethyl-3,9,10',11,16',18',22-heptaoxaspiro[heptacyclo[15.6.1.1⁷,¹⁰.0¹,¹⁴.0⁴,¹³.0¹⁸,²³.0¹³,²⁵]pentacosane-21,6'-hexacyclo[12.5.1.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁷,²⁰]henicosan]-18(23)-ene-2,7',9'-trione
5-[(1s,2r,3r)-7-hydroxy-2,3-bis(hydroxymethyl)-6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]-5'-[(3r,4r)-3-hydroxy-5-(4-hydroxy-3-methoxyphenyl)-4-(hydroxymethyl)oxolan-3-yl]-3,3'-dimethoxy-[1,1'-biphenyl]-2,2'-diol
(2r,3r,4s,5r,6r)-2-{[(4e,6s,7s,12e)-1,7-dihydroxytetradeca-4,12-dien-8,10-diyn-6-yl]oxy}-6-({[(2r,3r,4r,5s,6s)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol
methyl 4'-[(13e)-13-ethylidene-18-(methoxycarbonyl)-4-oxo-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0⁹,¹⁵]octadeca-2,5,7-trien-5-yl]-5'-methoxy-3,8'-dimethyl-8',15'-diazaspiro[oxirane-2,13'-pentacyclo[10.5.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵]octadecane]-2'(7'),3',5'-triene-18'-carboxylate
C42H48N4O7 (720.3522817999999)
2-[(1,7-dihydroxytetradeca-4,12-dien-8,10-diyn-6-yl)oxy]-6-({[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol
3-methyl-1-[(2r,2'r,6'r)-4,6,10',12'-tetrahydroxy-9'-(3-methylbutanoyl)-6'-{[2,4,6-trihydroxy-3-(3-methylbutanoyl)phenyl]methyl}-3h-5',7'-dioxaspiro[1-benzofuran-2,4'-tricyclo[6.4.0.0²,⁶]dodecane]-1'(12'),8',10'-trien-5-yl]butan-1-one
n-[10-benzyl-1,8,11-trihydroxy-3-(1h-indol-3-ylmethyl)-6,13-dimethyl-4,14-dioxo-3h,6h,7h,10h,13h,16h,17h,18h,18ah-pyrrolo[2,1-f]1-oxa-4,7,10,13-tetraazacyclohexadecan-7-yl]-2-phenylethanimidic acid
C40H44N6O7 (720.3271314000001)
(3s,3ar,4r,5r,6r,7as)-6-[(1s,2r,3r,4s,6s)-4-(acetyloxy)-6-hydroxy-2-(2-methoxy-2-oxoethyl)-1,3-dimethyl-7,9-dioxabicyclo[4.2.1]nonan-3-yl]-5-(formyloxy)-3-(furan-3-yl)-7a-hydroxy-3a-methyl-7-methylidene-1-oxo-tetrahydro-2h-inden-4-yl (2r,3r)-2-hydroxy-3-methylpentanoate
5-[(1s,2r,3r)-7-hydroxy-2,3-bis(hydroxymethyl)-6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]-5'-[(2s,3r,4r)-4-hydroxy-4-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)oxolan-2-yl]-3,3'-dimethoxy-[1,1'-biphenyl]-2,2'-diol
(2s,3s,4r,5r,6s)-2-{[(4e,6s,7r,12e)-1,7-dihydroxytetradeca-4,12-dien-8,10-diyn-6-yl]oxy}-6-({[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-({[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol
2-[(6-amino-2-{[(2,3-dihydroxyphenyl)(hydroxy)methylidene]amino}-1-hydroxyhexylidene)amino]-3-({2-[(6-amino-2-{[(2,3-dihydroxyphenyl)(hydroxy)methylidene]amino}-1-hydroxyhexylidene)amino]-3-hydroxypropanoyl}oxy)propanoic acid
4-(acetyloxy)-15-methoxy-2,14,17-trimethyl-3-oxo-11-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadecan-16-yl 2h-1,3-benzodioxole-5-carboxylate
bis((1's,3ar,4r,6's,7'r,7ar,9's)-7'-hydroxy-7a-methyl-10'-methylidene-tetrahydro-1h-3'-oxaspiro[2-benzofuran-4,5'-tricyclo[7.2.1.0¹,⁶]dodecane]-2',3,11'-trione)
(2r,3r,4s,5s,6r)-2-{[(4e,6s,7r,12e)-1,7-dihydroxytetradeca-4,12-dien-8,10-diyn-6-yl]oxy}-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol
3-methyl-1-[4,6,10',12'-tetrahydroxy-9'-(3-methylbutanoyl)-6'-{[2,4,6-trihydroxy-3-(3-methylbutanoyl)phenyl]methyl}-3h-5',7'-dioxaspiro[1-benzofuran-2,4'-tricyclo[6.4.0.0²,⁶]dodecane]-1'(12'),8',10'-trien-5-yl]butan-1-one
n-[(3s,6r,7s,10r,13r,18as)-10-benzyl-1,8,11-trihydroxy-3-(1h-indol-3-ylmethyl)-6,13-dimethyl-4,14-dioxo-3h,6h,7h,10h,13h,16h,17h,18h,18ah-pyrrolo[2,1-f]1-oxa-4,7,10,13-tetraazacyclohexadecan-7-yl]-2-phenylethanimidic acid
C40H44N6O7 (720.3271314000001)